PMID- 19346299
OWN - NLM
STAT- MEDLINE
DCOM- 20090615
LR  - 20220408
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Linking)
VI  - 14
IP  - 4
DP  - 2009 Apr
TI  - The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy 
      and personalized medicine.
PG  - 320-68
LID - 10.1634/theoncologist.2008-0230 [doi]
AB  - The human epidermal growth factor receptor (HER-2) oncogene encodes a 
      transmembrane tyrosine kinase receptor that has evolved as a major classifier of 
      invasive breast cancer and target of therapy for the disease. The validation of 
      the general prognostic significance of HER-2 gene amplification and protein 
      overexpression in the absence of anti-HER-2 targeted therapy is discussed in a 
      study of 107 published studies involving 39,730 patients, which produced an 
      overall HER-2-positive rate of 22.2% and a mean relative risk for overall 
      survival (OS) of 2.74. The issue of HER-2 status in primary versus metastatic 
      breast cancer is considered along with a section on the features of metastatic 
      HER-2-positive disease. The major marketed slide-based HER-2 testing approaches, 
      immunohistochemistry, fluorescence in situ hybridization, and chromogenic in situ 
      hybridization, are presented and contrasted in detail against the background of 
      the published American Society of Clinical Oncology-College of American 
      Pathologists guidelines for HER-2 testing. Testing issues, such as the impact of 
      chromosome 17 polysomy and local versus central HER-2 testing, are also 
      discussed. Emerging novel HER-2 testing techniques, including mRNA-based testing 
      by real-time polymerase chain reaction and DNA microarray methods, HER-2 receptor 
      dimerization, phosphorylated HER-2 receptors, and HER-2 status in circulating 
      tumor cells, are also considered. A series of biomarkers potentially associated 
      with resistance to trastuzumab is discussed with emphasis on the phosphatase and 
      tensin homologue deleted on chromosome ten/Akt and insulin-like growth factor 
      receptor pathways. The efficacy results for the more recently approved small 
      molecule HER-1/HER-2 kinase inhibitor lapatinib are also presented along with a 
      more limited review of markers of resistance for this agent. Additional topics in 
      this section include combinations of both anti-HER-2 targeted therapies together 
      as well as with novel agents including bevacizumab, everolimus, and tenespimycin. 
      A series of novel HER-2-targeting agents is also presented, including pertuzumab, 
      ertumaxomab, HER-2 vaccines, and recently discovered tyrosine kinase inhibitors. 
      Biomarkers predictive of HER-2 targeted therapy toxicity are included, and the 
      review concludes with a consideration of HER-2 status in the prediction of 
      response to non-HER-2 targeted treatments including hormonal therapy, 
      anthracyclines, and taxanes.
FAU - Ross, Jeffrey S
AU  - Ross JS
AD  - Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, 
      NY 12208, USA. rossj@mail.amc.edu
FAU - Slodkowska, Elzbieta A
AU  - Slodkowska EA
FAU - Symmans, W Fraser
AU  - Symmans WF
FAU - Pusztai, Lajos
AU  - Pusztai L
FAU - Ravdin, Peter M
AU  - Ravdin PM
FAU - Hortobagyi, Gabriel N
AU  - Hortobagyi GN
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090403
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine)
RN  - 0 (Anthracyclines)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 0 (Quinazolines)
RN  - 0 (RNA, Messenger)
RN  - 0 (Taxoids)
RN  - 0VUA21238F (Lapatinib)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - K16AIQ8CTM (pertuzumab)
RN  - L5L45YGP1O (ertumaxomab)
RN  - P188ANX8CK (Trastuzumab)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
CIN - Oncologist. 2016 Mar;21(3):391. PMID: 26966227
MH  - Anthracyclines/administration & dosage
MH  - Antibodies, Monoclonal/administration & dosage
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bevacizumab
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*chemistry/*drug therapy/mortality/pathology
MH  - Everolimus
MH  - Evidence-Based Medicine
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization
MH  - Lapatinib
MH  - Neoplasm Staging
MH  - Polymerase Chain Reaction
MH  - Practice Guidelines as Topic
MH  - Prognosis
MH  - Pyrazoles/administration & dosage
MH  - Pyrimidines/administration & dosage
MH  - Quinazolines/administration & dosage
MH  - RNA, Messenger/analysis
MH  - Receptor, ErbB-2/*analysis/*drug effects
MH  - Sirolimus/administration & dosage/analogs & derivatives
MH  - Survival Analysis
MH  - Taxoids/administration & dosage
MH  - Trastuzumab
MH  - Treatment Outcome
MH  - Up-Regulation/drug effects
RF  - 432
EDAT- 2009/04/07 09:00
MHDA- 2009/06/16 09:00
CRDT- 2009/04/07 09:00
PHST- 2009/04/07 09:00 [entrez]
PHST- 2009/04/07 09:00 [pubmed]
PHST- 2009/06/16 09:00 [medline]
AID - theoncologist.2008-0230 [pii]
AID - 10.1634/theoncologist.2008-0230 [doi]
PST - ppublish
SO  - Oncologist. 2009 Apr;14(4):320-68. doi: 10.1634/theoncologist.2008-0230. Epub 
      2009 Apr 3.